Gene expression survival analysis showed that with regard to disease-free interval (DFI), high expression of TRPV3 in BRCA and ESCA, TRPV2 in ESCA, TRPV5 in CESC, and TRPV1 in PRAD, was associated with a longer prognosis. This evidence concerns the gene TRPV5 and prostate adenocarcinoma.